John P Brancaccio - Net Worth and Insider Trading
John P Brancaccio Net Worth
The estimated net worth of John P Brancaccio is at least $90,954 dollars as of 2024-04-29. John P Brancaccio is the Director of Cardiff Oncology Inc and owns about 12,260 shares of Cardiff Oncology Inc (CRDF) stock worth over $55,415. John P Brancaccio is the Director of OKYO Pharma Ltd and owns about 16,670 shares of OKYO Pharma Ltd (OKYO) stock worth over $25,505. John P Brancaccio is also the Director of Hepion Pharmaceuticals Inc and owns about 7,008 shares of Hepion Pharmaceuticals Inc (HEPA) stock worth over $9,839. Besides these, John P Brancaccio also holds Synergy Pharmaceuticals Inc (SGYPQ) . Details can be seen in John P Brancaccio's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John P Brancaccio has not made any transactions after 2023-09-15 and currently still holds the listed stock(s).
Transaction Summary of John P Brancaccio
John P Brancaccio Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John P Brancaccio owns 4 companies in total, including Hepion Pharmaceuticals Inc (HEPA) , Cardiff Oncology Inc (CRDF) , and Synergy Pharmaceuticals Inc (SGYPQ) among others .
Click here to see the complete history of John P Brancaccio’s form 4 insider trades.
Insider Ownership Summary of John P Brancaccio
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2020-12-02 | director |
| CRDF | Cardiff Oncology Inc | 2021-03-22 | director |
| SGYPQ | Synergy Pharmaceuticals Inc | 2018-07-04 | director |
| OKYO | OKYO Pharma Ltd | 2023-09-15 | director |
John P Brancaccio Latest Holdings Summary
John P Brancaccio currently owns a total of 4 stocks. Among these stocks, John P Brancaccio owns 12,260 shares of Cardiff Oncology Inc (CRDF) as of March 22, 2021, with a value of $55,415 and a weighting of 60.93%. John P Brancaccio owns 16,670 shares of OKYO Pharma Ltd (OKYO) as of September 15, 2023, with a value of $25,505 and a weighting of 28.04%. John P Brancaccio also owns 7,008 shares of Hepion Pharmaceuticals Inc (HEPA) as of December 2, 2020, with a value of $9,839 and a weighting of 10.82%. The other 1 stocks Synergy Pharmaceuticals Inc (SGYPQ) have a combined weighting of 0.21% among all his current holdings.
Latest Holdings of John P Brancaccio
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology Inc | 2021-03-22 | 12,260 | 4.52 | 55,415 |
| OKYO | OKYO Pharma Ltd | 2023-09-15 | 16,670 | 1.53 | 25,505 |
| HEPA | Hepion Pharmaceuticals Inc | 2020-12-02 | 7,008 | 1.40 | 9,839 |
| SGYPQ | Synergy Pharmaceuticals Inc | 2017-05-26 | 30,444 | 0.01 | 195 |
Holding Weightings of John P Brancaccio
John P Brancaccio Form 4 Trading Tracker
According to the SEC Form 4 filings, John P Brancaccio has made a total of 2 transactions in Cardiff Oncology Inc (CRDF) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cardiff Oncology Inc is the acquisition of 3,000 shares on March 22, 2021, which cost John P Brancaccio around $32,850.
According to the SEC Form 4 filings, John P Brancaccio has made a total of 1 transactions in OKYO Pharma Ltd (OKYO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in OKYO Pharma Ltd is the acquisition of 16,670 shares on September 15, 2023, which cost John P Brancaccio around $25,005.
According to the SEC Form 4 filings, John P Brancaccio has made a total of 1 transactions in Hepion Pharmaceuticals Inc (HEPA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Hepion Pharmaceuticals Inc is the acquisition of 7,000 shares on December 2, 2020, which cost John P Brancaccio around $10,710.
More details on John P Brancaccio's insider transactions can be found in the Insider Trading History of John P Brancaccio table.Insider Trading History of John P Brancaccio
- 1
John P Brancaccio Trading Performance
GuruFocus tracks the stock performance after each of John P Brancaccio's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John P Brancaccio is 37.35%. GuruFocus also compares John P Brancaccio's trading performance to market benchmark return within the same time period. The performance of stocks bought by John P Brancaccio within 3 months outperforms 2 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John P Brancaccio's insider trading performs compared to the benchmark.
Performance of John P Brancaccio
Average Return
42.39%
Outperforming Transactions
17%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.16 | 37.35 | 132.76 | 42.39 | -33.31 | -7.54 |
| Relative Return to S&P 500(%) | 9.62 | 30.88 | 123.6 | 24.89 | -41.26 | -19.7 |
John P Brancaccio Ownership Network
Ownership Network List of John P Brancaccio
Ownership Network Relation of John P Brancaccio
John P Brancaccio Owned Company Details
What does Hepion Pharmaceuticals Inc do?
Who are the key executives at Hepion Pharmaceuticals Inc?
John P Brancaccio is the director of Hepion Pharmaceuticals Inc. Other key executives at Hepion Pharmaceuticals Inc include Chief Scientific Officer Robert T Foster , Chief Financial Officer John T Cavan , and director & CEO and President Gary S Jacob .
Hepion Pharmaceuticals Inc (HEPA) Insider Trades Summary
Over the past 18 months, John P Brancaccio made no insider transaction in Hepion Pharmaceuticals Inc (HEPA). Other recent insider transactions involving Hepion Pharmaceuticals Inc (HEPA) include a net purchase of 8,000 shares made by Peter Wijngaard , and a net purchase of 3,200 shares made by Robert T Foster .
In summary, during the past 3 months, insiders sold 0 shares of Hepion Pharmaceuticals Inc (HEPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hepion Pharmaceuticals Inc (HEPA) were sold and 11,200 shares were bought by its insiders, resulting in a net purchase of 11,200 shares.
Hepion Pharmaceuticals Inc (HEPA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Hepion Pharmaceuticals Inc Insider Transactions
John P Brancaccio Mailing Address
Above is the net worth, insider trading, and ownership report for John P Brancaccio. You might contact John P Brancaccio via mailing address: C/o Tamir Biotechnology, Inc., 11 Deer Park Drive, Suite 204, Monmouth Junction Nj 08852.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
